Amelia Deitchman, PharmD

Assistant Professor

Department of Clinical Pharmacy

[email protected]

Phone: +1 415 476-1148

1001 Potrero Ave, Rm 157

San Francisco, CA 94110

United States

Links

UCSF Profiles

UCSF centers, institutes, and research programs

Drug Research Unit (DRU)

What I do

My research seeks to inform novel therapeutic strategies to cure HIV through better understanding of pharmacokinetics and pharmacodynamics of individual and combinations of candidate drugs. Based out of the UCSF Drug Research Unit (DRU), I work with a multidisciplinary team of clinicians-scientists and researchers here at UCSF and across collaborative international networks on design, execution, and analysis of cure-focused clinical trials in people living with HIV. Our ultimate goal is to identify curative strategies to cure the nearly 37 million people with HIV.

Departmental research area

clinical research

My research expertise

infectious disease, pharmacokinetics/pharmacodynamics, HIV cure clinical pharmacology, pharmacometric modelling and simulation, clinical translational PK/PD

Degrees

T32 Clinical Pharmacology Fellowship, University of California, San Francisco, 2020

PhD, Pharmaceutical Sciences, minor in Applied Statistics, University of Florida, 2017

PharmD, University of Florida, 2013

Publications

Schnittman SR, Deitchman AN, Beck-Engeser G, Ahn H, York VA, Hartig H, Hecht FM, Martin JN, Deeks SG, Aweeka FT, Hunt PW. Some But Not All Biomarkers of Immune Activation Remain Abnormal Despite Very Early Treatment of HIV. J Infect Dis. 2020 Sep 11.

Henrich TJ, Schreiner C, Cameron C, Hogan LE, Richardson B, Rutishauser RL, Deitchman AN, Chu S, Rogers R, Thanh C, Gibson EA, Zarinsefat A, Bakkour S, Aweeka F, Busch MP, Liegler T, Baker C, Milush J, Deeks SG, Stock PG. Everolimus, an mTORC1/2 inhibitor, in ART-suppressed individuals who received solid organ transplantation: A prospective study. Am J Transplant. 2020 Aug 11.

Bigelow KM, Deitchman AN, Li SY, Barnes-Boyle K, Tyagi S, Soni H, Dooley KE, Savic R, Nuermberger EL. Pharmacodynamic Correlates of Linezolid Activity and Toxicity in Murine Models of Tuberculosis. J Infect Dis. 2020 Jan 29.

Deitchman AN. The Risk of Treating Populations Instead of Patients. CPT Pharmacometrics Syst Pharmacol. 2019 05; 8(5):256-258.

Deitchman AN, Singh RSP, Derendorf H. Nonlinear Protein Binding: Not What You Think. J Pharm Sci. 2018 07; 107(7):1754-1760.

McDonough CW, Magvanjav O, Sá ACC, El Rouby NM, Dave C, Deitchman AN, Kawaguchi-Suzuki M, Mei W, Shen Y, Singh RSP, Solayman M, Bailey KR, Boerwinkle E, Chapman AB, Gums JG, Webb A, Scherer SE, Sadee W, Turner ST, Cooper-DeHoff RM, Gong Y, Johnson JA. Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses). Circ Genom Precis Med. 2018 04; 11(4):e001854.

Deitchman AN, Singh RSP, Rand KH, Derendorf H. Enhanced in vitro activity of tigecycline in the presence of chelating agents. Int J Antimicrob Agents. 2018 May; 51(5):799-802.

Singh RSP, Mukker JK, Drescher SK, Deitchman AN, Derendorf H. A need to revisit clinical breakpoints of tigecycline: effect of atypical non-linear plasma protein binding. Int J Antimicrob Agents. 2017 Apr; 49(4):449-455.

Deitchman AN, Heinrichs MT, Khaowroongrueng V, Jadhav SB, Derendorf H. Utility of Microdialysis in Infectious Disease Drug Development and Dose Optimization. AAPS J. 2017 03; 19(2):334-342.

Deitchman A, de Jong D, Barbour A, Derendorf H. Ceftobiprole medocaril (BAL-5788) for the treatment of complicated skin infections. Expert Rev Anti Infect Ther. 2016; 14(11):997-1006.

Singh RSP, Mukker JK, Deitchman AN, Drescher SK, Derendorf H. Role of Divalent Metal Ions in Atypical Nonlinear Plasma Protein Binding Behavior of Tigecycline. J Pharm Sci. 2016 11; 105(11):3409-3414.

Deitchman AN, Derendorf H. Measuring drug distribution in the critically ill patient. Adv Drug Deliv Rev. 2014 Nov 20; 77:22-6.

B?dingen FV, Gonzalez D, Tucker AN, Derendorf H. Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage Adjustments. Ther Adv Infect Dis. 2014 Feb 01; 2(1):17-42.